ZA200103296B - Remedies for bone metabolic errors. - Google Patents
Remedies for bone metabolic errors. Download PDFInfo
- Publication number
- ZA200103296B ZA200103296B ZA200103296A ZA200103296A ZA200103296B ZA 200103296 B ZA200103296 B ZA 200103296B ZA 200103296 A ZA200103296 A ZA 200103296A ZA 200103296 A ZA200103296 A ZA 200103296A ZA 200103296 B ZA200103296 B ZA 200103296B
- Authority
- ZA
- South Africa
- Prior art keywords
- ocif
- polysaccharide
- administration
- human
- level
- Prior art date
Links
- 210000000988 bone and bone Anatomy 0.000 title description 6
- 230000002503 metabolic effect Effects 0.000 title 1
- 102000008108 Osteoprotegerin Human genes 0.000 claims description 164
- 108010035042 Osteoprotegerin Proteins 0.000 claims description 164
- 150000004676 glycans Chemical class 0.000 claims description 46
- 229920001282 polysaccharide Polymers 0.000 claims description 46
- 239000005017 polysaccharide Substances 0.000 claims description 46
- 229960000633 dextran sulfate Drugs 0.000 claims description 34
- 239000000126 substance Substances 0.000 claims description 19
- 229920001277 pectin Polymers 0.000 claims description 18
- 239000001814 pectin Substances 0.000 claims description 18
- 235000010987 pectin Nutrition 0.000 claims description 18
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 17
- 229920000669 heparin Polymers 0.000 claims description 17
- 229960002897 heparin Drugs 0.000 claims description 17
- 239000003795 chemical substances by application Substances 0.000 claims description 16
- 230000000694 effects Effects 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 12
- 230000002708 enhancing effect Effects 0.000 claims description 8
- 239000000679 carrageenan Substances 0.000 claims description 6
- 229920001525 carrageenan Polymers 0.000 claims description 6
- 235000010418 carrageenan Nutrition 0.000 claims description 6
- 229940113118 carrageenan Drugs 0.000 claims description 6
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 claims description 6
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 239000000243 solution Substances 0.000 description 44
- 210000002966 serum Anatomy 0.000 description 25
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 22
- 239000011575 calcium Substances 0.000 description 22
- 229910052791 calcium Inorganic materials 0.000 description 22
- 150000001413 amino acids Chemical class 0.000 description 20
- 210000004369 blood Anatomy 0.000 description 19
- 239000008280 blood Substances 0.000 description 19
- 238000002360 preparation method Methods 0.000 description 18
- 238000012360 testing method Methods 0.000 description 17
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 16
- 239000002904 solvent Substances 0.000 description 15
- 239000002299 complementary DNA Substances 0.000 description 14
- 239000012488 sample solution Substances 0.000 description 13
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
- 230000001184 hypocalcaemic effect Effects 0.000 description 12
- 239000000203 mixture Substances 0.000 description 11
- 230000002688 persistence Effects 0.000 description 10
- 239000000539 dimer Substances 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 208000037147 Hypercalcaemia Diseases 0.000 description 8
- 241000700157 Rattus norvegicus Species 0.000 description 8
- 235000001014 amino acid Nutrition 0.000 description 8
- 229940024606 amino acid Drugs 0.000 description 8
- 230000000148 hypercalcaemia Effects 0.000 description 8
- 208000030915 hypercalcemia disease Diseases 0.000 description 8
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 239000000178 monomer Substances 0.000 description 7
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 6
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 6
- 238000007918 intramuscular administration Methods 0.000 description 6
- 238000001990 intravenous administration Methods 0.000 description 6
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 6
- 229920000053 polysorbate 80 Polymers 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 239000012064 sodium phosphate buffer Substances 0.000 description 6
- 238000012217 deletion Methods 0.000 description 5
- 230000037430 deletion Effects 0.000 description 5
- PYMYPHUHKUWMLA-UHFFFAOYSA-N 2,3,4,5-tetrahydroxypentanal Chemical compound OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- 208000001132 Osteoporosis Diseases 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 239000009194 citrus pectin Substances 0.000 description 4
- 229940040387 citrus pectin Drugs 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 3
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 3
- 239000004472 Lysine Substances 0.000 description 3
- 108010076504 Protein Sorting Signals Proteins 0.000 description 3
- 235000004279 alanine Nutrition 0.000 description 3
- 235000009582 asparagine Nutrition 0.000 description 3
- 229960001230 asparagine Drugs 0.000 description 3
- 230000036765 blood level Effects 0.000 description 3
- 238000004891 communication Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 238000010253 intravenous injection Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 3
- 229940068968 polysorbate 80 Drugs 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 2
- 208000006386 Bone Resorption Diseases 0.000 description 2
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 2
- 229920001503 Glucan Polymers 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 230000024279 bone resorption Effects 0.000 description 2
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 2
- -1 dextran Chemical class 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 230000013632 homeostatic process Effects 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 210000002997 osteoclast Anatomy 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 230000036962 time dependent Effects 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- CPBJMKMKNCRKQB-UHFFFAOYSA-N 3,3-bis(4-hydroxy-3-methylphenyl)-2-benzofuran-1-one Chemical compound C1=C(O)C(C)=CC(C2(C3=CC=CC=C3C(=O)O2)C=2C=C(C)C(O)=CC=2)=C1 CPBJMKMKNCRKQB-UHFFFAOYSA-N 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 229940122361 Bisphosphonate Drugs 0.000 description 1
- 102000055006 Calcitonin Human genes 0.000 description 1
- 108060001064 Calcitonin Proteins 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- 229920000045 Dermatan sulfate Polymers 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 229920002971 Heparan sulfate Polymers 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 229920000288 Keratan sulfate Polymers 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108091034057 RNA (poly(A)) Proteins 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 150000004663 bisphosphonates Chemical class 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000037182 bone density Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- 229960004015 calcitonin Drugs 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- AVJBPWGFOQAPRH-FWMKGIEWSA-L dermatan sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@H](OS([O-])(=O)=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](C([O-])=O)O1 AVJBPWGFOQAPRH-FWMKGIEWSA-L 0.000 description 1
- 229940051593 dermatan sulfate Drugs 0.000 description 1
- 229960002086 dextran Drugs 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000003028 elevating effect Effects 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- KXCLCNHUUKTANI-RBIYJLQWSA-N keratan Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@H](COS(O)(=O)=O)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@H](O[C@@H](O[C@H]3[C@H]([C@@H](COS(O)(=O)=O)O[C@@H](O)[C@@H]3O)O)[C@H](NC(C)=O)[C@H]2O)COS(O)(=O)=O)O[C@H](COS(O)(=O)=O)[C@@H]1O KXCLCNHUUKTANI-RBIYJLQWSA-N 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 229960000292 pectin Drugs 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920000447 polyanionic polymer Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- SWGJCIMEBVHMTA-UHFFFAOYSA-K trisodium;6-oxido-4-sulfo-5-[(4-sulfonatonaphthalen-1-yl)diazenyl]naphthalene-2-sulfonate Chemical compound [Na+].[Na+].[Na+].C1=CC=C2C(N=NC3=C4C(=CC(=CC4=CC=C3O)S([O-])(=O)=O)S([O-])(=O)=O)=CC=C(S([O-])(=O)=O)C2=C1 SWGJCIMEBVHMTA-UHFFFAOYSA-K 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Dermatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP32287498 | 1998-10-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200103296B true ZA200103296B (en) | 2001-10-25 |
Family
ID=18148585
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200103296A ZA200103296B (en) | 1998-10-28 | 2001-04-23 | Remedies for bone metabolic errors. |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US6919312B2 (zh) |
| EP (1) | EP1127578A4 (zh) |
| JP (1) | JP3860415B2 (zh) |
| KR (1) | KR20010082272A (zh) |
| CN (1) | CN1183961C (zh) |
| AU (1) | AU755422B2 (zh) |
| BR (1) | BR9914834A (zh) |
| CA (1) | CA2347107A1 (zh) |
| CZ (1) | CZ20011378A3 (zh) |
| HK (1) | HK1042847A1 (zh) |
| HU (1) | HUP0104126A3 (zh) |
| IL (1) | IL142557A0 (zh) |
| MX (1) | MXPA01004225A (zh) |
| NO (1) | NO20012106L (zh) |
| NZ (1) | NZ511506A (zh) |
| PL (1) | PL347559A1 (zh) |
| RU (1) | RU2223782C2 (zh) |
| TR (1) | TR200101146T2 (zh) |
| TW (1) | TW529954B (zh) |
| WO (1) | WO2000024416A1 (zh) |
| ZA (1) | ZA200103296B (zh) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL117175A (en) | 1995-02-20 | 2005-11-20 | Sankyo Co | Osteoclastogenesis inhibitory factor protein |
| TR200101146T2 (tr) | 1998-10-28 | 2001-09-21 | Sankyo Co., Ltd. | Kemik-patobolizmasını tedavi edici madde. |
| US6593310B1 (en) * | 2000-11-21 | 2003-07-15 | Arthropharm Pty. Ltd. | Treatment of osteoporosis |
| IL158152A0 (en) * | 2001-04-03 | 2004-03-28 | Nestle Sa | Osteoprotegerin in milk |
| CZ20022231A3 (cs) * | 2001-06-29 | 2003-02-12 | Sankyo Company Limited | Komplex skládající se z osteoklastogenezi inhibujícího faktoru a polysacharidu |
| EP1482978A1 (en) * | 2002-03-01 | 2004-12-08 | Sankyo Company, Limited | Pharmaceutical composition comprising osteoclastogenesis inhibitory factor |
| AU2003242265A1 (en) * | 2002-06-07 | 2003-12-22 | Sankyo Company, Limited | Combined effects of therapeutic or preventive agent composition for bone breakage |
| CN101184780B (zh) | 2005-05-05 | 2012-10-03 | 森馨香料公司 | β-葡聚糖和甘露聚糖的制备 |
| TW200820980A (en) * | 2006-10-02 | 2008-05-16 | Nat Inst For Materials Science | A sustained-release preparation having osteoconductive activity |
| WO2008077257A1 (en) * | 2006-12-22 | 2008-07-03 | Mathys Ag Bettlach | Precursor for the preparation of a pasty bone replacement material by admixture of a liquid |
| SG181615A1 (en) * | 2009-12-09 | 2012-07-30 | Agency Science Tech & Res | Glycosaminoglycan mixtures |
| CN113088487B (zh) * | 2020-04-30 | 2022-12-06 | 威海见生生物技术有限公司 | 一种间充质干细胞成脂转化抑制剂 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2604135B2 (ja) * | 1986-02-28 | 1997-04-30 | ライオン株式会社 | 口腔骨疾患治療剤 |
| IL91438A (en) * | 1989-08-25 | 1995-03-30 | Bukh Meditec | Preparation for treating dental disease |
| TW318142B (zh) | 1991-06-03 | 1997-10-21 | Mitsubishi Chemicals Co Ltd | |
| IL117175A (en) | 1995-02-20 | 2005-11-20 | Sankyo Co | Osteoclastogenesis inhibitory factor protein |
| US6369027B1 (en) | 1995-12-22 | 2002-04-09 | Amgen Inc. | Osteoprotegerin |
| US6613544B1 (en) | 1995-12-22 | 2003-09-02 | Amgen Inc. | Osteoprotegerin |
| US20030207827A1 (en) | 1995-12-22 | 2003-11-06 | William J. Boyle | Osteoprotegerin |
| JPH1057071A (ja) | 1996-08-19 | 1998-03-03 | Snow Brand Milk Prod Co Ltd | 新規ｄｎａ及びそれを用いた蛋白質の製造方法 |
| EP0911342B2 (en) | 1997-04-15 | 2013-05-22 | Daiichi Sankyo Company, Limited | Novel protein and process for producing the same |
| US6656508B2 (en) * | 1997-04-17 | 2003-12-02 | Amgen Inc. | Sustained-release alginate gels |
| KR100547395B1 (ko) | 1997-09-24 | 2006-02-01 | 산쿄 가부시키가이샤 | 골대사이상증의 진단방법 |
| DE69904818T2 (de) | 1998-06-15 | 2003-10-09 | Takeda Chemical Industries, Ltd. | Thienodipyridinderivate, ihre herstellung und verwendung |
| TR200101146T2 (tr) | 1998-10-28 | 2001-09-21 | Sankyo Co., Ltd. | Kemik-patobolizmasını tedavi edici madde. |
| AU6078500A (en) | 1999-07-09 | 2001-01-30 | Amgen, Inc. | Combination therapy for conditions leading to bone loss |
| AU6788900A (en) * | 1999-09-03 | 2001-04-10 | Amgen, Inc. | Compositions and methods for the prevention or treatment of cancer and bone loss associated with cancer |
| CA2394536A1 (en) | 1999-12-16 | 2001-06-21 | Amgen Inc. | Tnfr/opg-like molecules and uses thereof |
| CZ20022231A3 (cs) | 2001-06-29 | 2003-02-12 | Sankyo Company Limited | Komplex skládající se z osteoklastogenezi inhibujícího faktoru a polysacharidu |
| EP1482978A1 (en) | 2002-03-01 | 2004-12-08 | Sankyo Company, Limited | Pharmaceutical composition comprising osteoclastogenesis inhibitory factor |
-
1999
- 1999-10-28 TR TR2001/01146T patent/TR200101146T2/xx unknown
- 1999-10-28 CZ CZ20011378A patent/CZ20011378A3/cs unknown
- 1999-10-28 AU AU64877/99A patent/AU755422B2/en not_active Ceased
- 1999-10-28 JP JP2000578024A patent/JP3860415B2/ja not_active Expired - Fee Related
- 1999-10-28 EP EP99952793A patent/EP1127578A4/en not_active Withdrawn
- 1999-10-28 WO PCT/JP1999/005963 patent/WO2000024416A1/ja not_active Application Discontinuation
- 1999-10-28 TW TW088118658A patent/TW529954B/zh not_active IP Right Cessation
- 1999-10-28 IL IL14255799A patent/IL142557A0/xx unknown
- 1999-10-28 RU RU2001114216/15A patent/RU2223782C2/ru not_active IP Right Cessation
- 1999-10-28 HU HU0104126A patent/HUP0104126A3/hu unknown
- 1999-10-28 MX MXPA01004225A patent/MXPA01004225A/es unknown
- 1999-10-28 KR KR1020017005365A patent/KR20010082272A/ko not_active Application Discontinuation
- 1999-10-28 CA CA002347107A patent/CA2347107A1/en not_active Abandoned
- 1999-10-28 PL PL99347559A patent/PL347559A1/xx not_active Application Discontinuation
- 1999-10-28 BR BR9914834-0A patent/BR9914834A/pt not_active IP Right Cessation
- 1999-10-28 NZ NZ511506A patent/NZ511506A/xx unknown
- 1999-10-28 CN CNB998128287A patent/CN1183961C/zh not_active Expired - Fee Related
-
2001
- 2001-04-12 US US09/834,008 patent/US6919312B2/en not_active Expired - Fee Related
- 2001-04-23 ZA ZA200103296A patent/ZA200103296B/en unknown
- 2001-04-27 NO NO20012106A patent/NO20012106L/no unknown
-
2002
- 2002-06-05 HK HK02104289.0A patent/HK1042847A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HK1042847A1 (zh) | 2002-08-30 |
| PL347559A1 (en) | 2002-04-08 |
| JP3860415B2 (ja) | 2006-12-20 |
| WO2000024416A1 (fr) | 2000-05-04 |
| HUP0104126A3 (en) | 2004-07-28 |
| TW529954B (en) | 2003-05-01 |
| US20010031725A1 (en) | 2001-10-18 |
| RU2223782C2 (ru) | 2004-02-20 |
| AU755422B2 (en) | 2002-12-12 |
| IL142557A0 (en) | 2002-03-10 |
| US6919312B2 (en) | 2005-07-19 |
| MXPA01004225A (es) | 2002-06-04 |
| NO20012106L (no) | 2001-06-21 |
| EP1127578A4 (en) | 2004-12-15 |
| AU6487799A (en) | 2000-05-15 |
| CN1325310A (zh) | 2001-12-05 |
| CZ20011378A3 (cs) | 2001-10-17 |
| NO20012106D0 (no) | 2001-04-27 |
| TR200101146T2 (tr) | 2001-09-21 |
| EP1127578A1 (en) | 2001-08-29 |
| KR20010082272A (ko) | 2001-08-29 |
| BR9914834A (pt) | 2001-08-14 |
| NZ511506A (en) | 2004-02-27 |
| HUP0104126A2 (hu) | 2002-03-28 |
| CA2347107A1 (en) | 2000-05-04 |
| CN1183961C (zh) | 2005-01-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI118171B (fi) | Farmaseuttinen formulointi tekijän VIII antamiseksi ihonalaisesti, lihaksensisäisesti tai ihonsisäisesti | |
| AU755422B2 (en) | Remedies for bone metabolic errors | |
| JP2024059624A (ja) | アクチビンｉｉｂ型受容体変異体およびそれらの使用方法 | |
| JPH09502440A (ja) | ヘパリン結合の阻害 | |
| KR20150006059A (ko) | 섬유모세포 성장 인자 21 변이체 | |
| EP3439702B1 (en) | Conjugated c1 esterase inhibitor and uses thereof | |
| EP2781221B1 (en) | Medicine for treatment and/or improvement of sepsis | |
| KR20180124120A (ko) | 재조합 산 알파-글루코시다제를 포함하는 제형 | |
| KR100939983B1 (ko) | 히아루론산-소수성 폴리 아미노산 공중합체 | |
| KR20140083036A (ko) | 인자 ｖｉｉｉ의 생체이용률을 향상시키기 위한 황산화 글리코사미노글리칸의 용도 | |
| EP1675611B1 (en) | Therapeutic applications for c-peptide | |
| PT1365788E (pt) | Análogos da trombomodulina para utilização na recuperação de lesão da medula espinal | |
| CZ20022231A3 (cs) | Komplex skládající se z osteoklastogenezi inhibujícího faktoru a polysacharidu | |
| EP3685850A1 (en) | Teriparatide-containing liquid pharmaceutical composition having excellent pharmacodynamics and/or stability | |
| JP7237085B2 (ja) | 凝固異常を伴う敗血症の治療及び／又は改善のための医薬 | |
| JP3806945B2 (ja) | ヒト由来アンチトロンビン−ｉｉｉの新規用途 | |
| JPH083065A (ja) | 肝臓障害に対する治療剤 | |
| WO2023064806A1 (en) | Collagen 7 protein replacement therapy | |
| NZ786823A (en) | Conjugated c1 esterase inhibitor and uses thereof | |
| NZ747180B2 (en) | Conjugated c1 esterase inhibitor and uses thereof | |
| JP2000344681A (ja) | Ｈｇｆ含有医薬 | |
| WO2003006050A1 (fr) | Medicaments de prevention/remedes contre l'oedeme du cerveau |